- Home
- TSLX vs DYN Comparison
TSLX vs DYN Comparison
Compare TSLX & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSLX
- DYN
- Stock Information
- Founded
- TSLX 2010
- DYN 1984
- Country
- TSLX United States
- DYN United States
- Employees
- TSLX N/A
- DYN N/A
- Industry
- TSLX Investment Managers
- DYN Medicinal Chemicals and Botanical Products
- Sector
- TSLX Finance
- DYN Health Care
- Exchange
- TSLX Nasdaq
- DYN Nasdaq
- Market Cap
- TSLX 2.2B
- DYN 1.9B
- IPO Year
- TSLX 2014
- DYN 2020
- Fundamental
- Price
- TSLX $20.87
- DYN $14.20
- Analyst Decision
- TSLX Buy
- DYN Strong Buy
- Analyst Count
- TSLX 9
- DYN 14
- Target Price
- TSLX $23.67
- DYN $34.93
- AVG Volume (30 Days)
- TSLX 590.6K
- DYN 2.6M
- Earning Date
- TSLX 11-04-2025
- DYN 11-11-2025
- Dividend Yield
- TSLX 9.92%
- DYN N/A
- EPS Growth
- TSLX N/A
- DYN N/A
- EPS
- TSLX 2.01
- DYN N/A
- Revenue
- TSLX $474,291,000.00
- DYN N/A
- Revenue This Year
- TSLX N/A
- DYN N/A
- Revenue Next Year
- TSLX N/A
- DYN N/A
- P/E Ratio
- TSLX $10.40
- DYN N/A
- Revenue Growth
- TSLX 0.15
- DYN N/A
- 52 Week Low
- TSLX $18.58
- DYN $6.36
- 52 Week High
- TSLX $25.17
- DYN $35.90
- Technical
- Relative Strength Index (RSI)
- TSLX 22.05
- DYN 58.96
- Support Level
- TSLX $22.02
- DYN $12.43
- Resistance Level
- TSLX $22.62
- DYN $15.21
- Average True Range (ATR)
- TSLX 0.48
- DYN 0.73
- MACD
- TSLX -0.18
- DYN 0.15
- Stochastic Oscillator
- TSLX 6.67
- DYN 69.30
About TSLX Sixth Street Specialty Lending Inc.
Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.